Hormonal
Semaglutide treatment significantly reduces body weight and BMI in patients with acquired hypothalamic obesity, with effects stabilizing after 12 months.
For patients with hypothalamic obesity, semaglutide (weekly injection) is an effective treatment for significant weight loss, even with prior hypothalamic damage. Treatment should be titrated to a tolerated dose (up to 2.5 mg), and patients should be aware that stopping treatment leads to rapid weight regain, so adherence and side-effect management are critical.
All but one patient lost weight during semaglutide treatment with a mean weight loss of 13.4 kg... corresponding to a loss in BMI of 4.4 kg/m2... with a median dosage of semaglutide of 1.6 (range 0.5–2.5) mg.
Why this rating
Observational real-world data with no placebo control, but large sample size for this rare condition and statistically significant results.
Source
Semaglutide treatment of hypothalamic obesity – a real-life data study
Mathilde Svendstrup et al. · Pituitary · 2024
DOI 10.1007/s11102-024-01429-5
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →